Business Context and Reporting Period
This Form 8-K Current Report was filed by Supernus Pharmaceuticals, Inc. on February 24, 2025. The report discloses modifications to the compensatory arrangements of the Company's executive officers, effective as of January 1, 2025, following an annual compensation review by the Compensation Committee and Board of Directors.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on executive compensation adjustments.
Material Changes Versus Prior Period
The primary material change is the increase in annual base salaries and the granting of equity awards for executive officers. Specific adjustments include:
- Jack A. Khattar (CEO): Base salary increased from $1,001,500 to $1,036,000. Received a 2024 bonus of $826,254. Granted options to purchase 331,660 shares and 198,996 PSUs.
- Timothy C. Dec (CFO): Base salary increased from $485,500 to $504,900. Received a 2024 bonus of $229,160. Granted options to purchase 40,000 shares, 4,500 RSUs, and 5,000 PSUs.
- Padmanabh P. Bhatt (CSO): Base salary increased from $440,500 to $455,900. Received a 2024 bonus of $163,434. Granted options to purchase 20,000 shares, 4,500 RSUs, and 5,000 PSUs.
- Jonathan Rubin (CMO): Base salary increased from $466,400 to $485,100. Received a 2024 bonus of $192,530. Granted options to purchase 20,000 shares, 4,500 RSUs, and 5,000 PSUs.
- Frank Mottola (SVP, Quality/GMP/IT): Base salary increased from $377,400 to $392,500. Received a 2024 bonus of $140,001. Granted options to purchase 20,000 shares, 4,500 RSUs, and 5,000 PSUs.
Stock option exercise prices were set at $33.52 per share (granted Feb 19) and $34.59 per share (granted Feb 20), based on closing prices on those dates.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or discussion of general business risks. It notes that PSU awards vest based on the achievement of specified performance goals determined by the Committee. The compensation increases were benchmarked against an industry peer group and recommended by Aon plc.
Investor Verification Checklist
- Verify the total number of shares authorized under the Amended and Restated 2021 Equity Incentive Plan to assess remaining capacity for future grants.
- Review the specific performance goals attached to the Performance Share Units (PSUs) to understand the conditions for vesting.
- Confirm the impact of these salary increases on the Company's total compensation expense in upcoming quarterly reports.
- Check the current trading price of SUPN relative to the new option exercise prices ($33.52 and $34.59) to evaluate the immediate intrinsic value of the grants.